An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

  • Observational
  • Recruiting
  • NCT03692897
Eligibility Details Visit Clinicaltrials.gov

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion

         1. Male or female patients, age ≥18 years

         2. Being managed for chronic hepatitis B (CHB), including patients who have achieved functional cure and patients with concurrent delta hepatitis

        Exclusion

         1. Inability to provide written informed consent

         2. Known history of Human Immunodeficiency Virus (HIV)

         3. History of liver transplantation

At a Glance

National Government IDNCT03692897

IRB#IRB18-1449

Lead SponsorTarget PharmaSolutions, Inc.

Lead PhysicianSonali Paul

Collaborator(s)N/A

EligibilityAll
18 Years and up
Recruiting